These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28628042)

  • 1. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
    Chang AY; Dao T; Gejman RS; Jarvis CA; Scott A; Dubrovsky L; Mathias MD; Korontsvit T; Zakhaleva V; Curcio M; Hendrickson RC; Liu C; Scheinberg DA
    J Clin Invest; 2017 Jun; 127(7):2705-2718. PubMed ID: 28628042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
    Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
    Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
    Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
    Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
    Orlando D; Miele E; De Angelis B; Guercio M; Boffa I; Sinibaldi M; Po A; Caruana I; Abballe L; Carai A; Caruso S; Camera A; Moseley A; Hagedoorn RS; Heemskerk MHM; Giangaspero F; Mastronuzzi A; Ferretti E; Locatelli F; Quintarelli C
    Cancer Res; 2018 Jun; 78(12):3337-3349. PubMed ID: 29615432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
    Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
    J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
    Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
    Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
    Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
    J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing vaccine potency using TCRmimic antibodies.
    Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
    Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.
    Chames P; Hufton SE; Coulie PG; Uchanska-Ziegler B; Hoogenboom HR
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7969-74. PubMed ID: 10884427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
    Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME peptide-specific CD8
    Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
    Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
    McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
    Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
    Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
    Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
    Kessler JH; Beekman NJ; Bres-Vloemans SA; Verdijk P; van Veelen PA; Kloosterman-Joosten AM; Vissers DC; ten Bosch GJ; Kester MG; Sijts A; Wouter Drijfhout J; Ossendorp F; Offringa R; Melief CJ
    J Exp Med; 2001 Jan; 193(1):73-88. PubMed ID: 11136822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
    Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.